Array BioPharma Stock Price, News & Analysis (NASDAQ:ARRY)

$15.56 2.42 (18.42 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$15.56
Today's Range$14.26 - $16.00
52-Week Range$6.73 - $16.00
Volume17.64 million shs
Average Volume3.39 million shs
Market Capitalization$3.07 billion
P/E Ratio-21.03
Dividend YieldN/A
Beta1.91

About Array BioPharma (NASDAQ:ARRY)

Array BioPharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ARRY
CUSIP04269X10
Phone+1-303-3816600

Debt

Debt-to-Equity Ratio0.54%
Current Ratio5.43%
Quick Ratio5.43%

Price-To-Earnings

Trailing P/E Ratio-21.027027027027
Forward P/E Ratio-15.72
P/E GrowthN/A

Sales & Book Value

Annual Sales$150.85 million
Price / Sales20.32
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book222.29

Profitability

Trailing EPS($0.74)
Net Income$-116,810,000.00
Net Margins-89.30%
Return on Equity-158.70%
Return on Assets-38.54%

Miscellaneous

Employees209
Outstanding Shares197,030,000

Array BioPharma (NASDAQ:ARRY) Frequently Asked Questions

What is Array BioPharma's stock symbol?

Array BioPharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array BioPharma's earnings last quarter?

Array BioPharma Inc. (NASDAQ:ARRY) posted its quarterly earnings results on Tuesday, October, 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.22). The biopharmaceutical company had revenue of $29.75 million for the quarter, compared to the consensus estimate of $33.74 million. Array BioPharma had a negative net margin of 89.30% and a negative return on equity of 158.70%. The firm's revenue was down 24.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.20) EPS. View Array BioPharma's Earnings History.

When will Array BioPharma make its next earnings announcement?

Array BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, February, 8th 2018. View Earnings Estimates for Array BioPharma.

Where is Array BioPharma's stock going? Where will Array BioPharma's stock price be in 2018?

8 Wall Street analysts have issued 12 month price objectives for Array BioPharma's stock. Their forecasts range from $11.00 to $20.00. On average, they anticipate Array BioPharma's stock price to reach $15.25 in the next year. View Analyst Ratings for Array BioPharma.

What are Wall Street analysts saying about Array BioPharma stock?

Here are some recent quotes from research analysts about Array BioPharma stock:

  • 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (1/4/2018)
  • 2. Cantor Fitzgerald analysts commented, "ARRY and ASLAN (NC) have updated a 2011 agreement for varlitinib, a pan-HER2 inhibitor, providing nearer term cash to ARRY in exchange for commercialization rights (the prior agreement covered development)." (1/3/2018)
  • 3. Cowen Inc analysts commented, "We see ARRY's decision to withdraw the NRAS NDA as prudent given the known modest efficacy benefit. The NRAS-mutant melanoma opportunity represented a modest 6% of our base model DCF, thus we lower our PT modestly from $15 to $14. We view recent share weakness and the passing of this 'risk' event as an especially attractive opportunity to firmly reiterate our Outperform rating on ARRY shares." (3/20/2017)

Are investors shorting Array BioPharma?

Array BioPharma saw a decline in short interest in December. As of December 15th, there was short interest totalling 15,831,594 shares, a decline of 23.4% from the November 30th total of 20,663,397 shares. Based on an average daily volume of 3,128,678 shares, the days-to-cover ratio is currently 5.1 days. Approximately 8.1% of the company's stock are short sold.

Who are some of Array BioPharma's key competitors?

Who are Array BioPharma's key executives?

Array BioPharma's management team includes the folowing people:

  • Kyle A. Lefkoff, Independent Chairman of the Board (Age 56)
  • Ron R. Squarer, Chief Executive Officer, Director (Age 50)
  • Jason Haddock, Chief Financial Officer (Age 47)
  • Andrew R. Robbins, Chief Operating Officer (Age 41)
  • Nicholas A. Saccomano Ph.D., Chief Scientific Officer (Age 58)
  • Curtis Gale Oltmans, General Counsel (Age 54)
  • Victor Sandor, Chief Medical Officer (Age 51)
  • Shalini Sharp, Director (Age 42)
  • Charles M. Baum M.D., Ph.D., Independent Director (Age 59)
  • Gwendolyn A. Fyfe M.D., Independent Director (Age 65)

Who owns Array BioPharma stock?

Array BioPharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.49%) and North Star Investment Management Corp. (0.03%). Company insiders that own Array BioPharma stock include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Redmile Group, Llc and Ron Squarer. View Institutional Ownership Trends for Array BioPharma.

Who bought Array BioPharma stock? Who is buying Array BioPharma stock?

Array BioPharma's stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc. and North Star Investment Management Corp.. View Insider Buying and Selling for Array BioPharma.

How do I buy Array BioPharma stock?

Shares of Array BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array BioPharma's stock price today?

One share of Array BioPharma stock can currently be purchased for approximately $15.56.

How big of a company is Array BioPharma?

Array BioPharma has a market capitalization of $3.07 billion and generates $150.85 million in revenue each year. The biopharmaceutical company earns $-116,810,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Array BioPharma employs 209 workers across the globe.

How can I contact Array BioPharma?

Array BioPharma's mailing address is 3200 Walnut St, BOULDER, CO 80301-2514, United States. The biopharmaceutical company can be reached via phone at +1-303-3816600 or via email at [email protected]


MarketBeat Community Rating for Array BioPharma (ARRY)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  302 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  454
MarketBeat's community ratings are surveys of what our community members think about Array BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Array BioPharma (NASDAQ:ARRY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.882.862.86
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.25$14.63$13.86$11.86
Price Target Upside: 16.06% upside19.19% upside22.74% upside39.33% upside

Array BioPharma (NASDAQ:ARRY) Consensus Price Target History

Price Target History for Array BioPharma (NASDAQ:ARRY)

Array BioPharma (NASDAQ:ARRY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/21/2018Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
1/22/2018Leerink SwannUpgradeMarket Perform -> OutperformHighView Rating Details
1/22/2018Stifel NicolausBoost Price TargetPositive -> Buy$15.00 -> $20.00HighView Rating Details
12/22/2017Jefferies GroupBoost Price TargetBuy$13.00N/AView Rating Details
11/1/2017SunTrust BanksReiterated RatingBuy$16.00N/AView Rating Details
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$14.00 -> $18.00LowView Rating Details
9/11/2017CowenReiterated RatingOutperform$14.00 -> $15.00HighView Rating Details
9/11/2017JPMorgan Chase & Co.Reiterated RatingBuy$14.00HighView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Array BioPharma (NASDAQ:ARRY) Earnings History and Estimates Chart

Earnings by Quarter for Array BioPharma (NASDAQ:ARRY)

Array BioPharma (NASDAQ ARRY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018N/AView Earnings Details
10/31/2017Q1 2018($0.22)($0.22)$33.74 million$29.75 millionViewN/AView Earnings Details
8/9/2017Q4 2017($0.21)($0.17)$28.64 million$33.80 millionViewListenView Earnings Details
5/10/2017Q3 2017($0.16)($0.21)$38.28 million$33.28 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.20)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
10/31/2011Q1 2012($0.19)($0.06)ViewN/AView Earnings Details
8/8/2011Q4 2011($0.27)($0.17)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
11/8/2010Q1 2011($0.28)($0.20)ViewN/AView Earnings Details
8/9/2010Q4 2010($0.32)($0.30)ViewN/AView Earnings Details
5/3/2010Q3 2010($0.34)($0.30)ViewN/AView Earnings Details
2/1/2010Q2 2010($0.55)($0.44)ViewN/AView Earnings Details
11/2/2009Q1 2010($0.55)($0.52)ViewN/AView Earnings Details
8/10/2009Q4 2009($0.55)($0.55)ViewN/AView Earnings Details
5/4/2009Q3 2009($0.58)($0.55)ViewN/AView Earnings Details
2/2/2009Q2 2009($0.65)($0.57)ViewN/AView Earnings Details
11/3/2008Q1 2009($0.65)($0.63)ViewN/AView Earnings Details
8/11/2008Q4 2008($0.63)($0.68)ViewN/AView Earnings Details
5/5/2008Q3 2008($0.51)($0.51)ViewN/AView Earnings Details
2/4/2008Q2 2008($0.46)($0.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Array BioPharma (NASDAQ:ARRY) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.31)($0.19)($0.25)
Q2 20182($0.32)($0.18)($0.25)
Q3 20182($0.36)($0.18)($0.27)
Q4 20182($0.26)($0.21)($0.24)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Array BioPharma (NASDAQ:ARRY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Array BioPharma (NASDAQ ARRY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.18%
Institutional Ownership Percentage: 98.14%
Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)

Array BioPharma (NASDAQ ARRY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2018Lunsen Gil J VanDirectorSell21,500$12.94$278,210.0034,297View SEC Filing  
1/16/2018Jason HaddockCFOSell7,500$13.73$102,975.0036,368View SEC Filing  
12/19/2017Ron SquarerCEOSell819,671$10.86$8,901,627.06View SEC Filing  
12/18/2017Andrew R. RobbinsCOOSell282,874$10.72$3,032,409.28View SEC Filing  
9/29/2017Kyle LefkoffDirectorSell38,865$12.31$478,428.1551,585View SEC Filing  
3/28/2017Charles M BaumDirectorSell25,000$9.27$231,750.0030,000View SEC Filing  
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Array BioPharma (NASDAQ ARRY) News Headlines

Source:
DateHeadline
Cantor Fitzgerald Reaffirms "Buy" Rating for Array BioPharma (ARRY)Cantor Fitzgerald Reaffirms "Buy" Rating for Array BioPharma (ARRY)
www.americanbankingnews.com - January 22 at 10:34 PM
Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...) - StreetInsider.comPre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 22 at 3:23 PM
Why Array BioPharma Inc. Is SoaringWhy Array BioPharma Inc. Is Soaring
www.fool.com - January 22 at 12:33 PM
Stifel Nicolaus Boosts Array BioPharma (ARRY) Price Target to $20.00Stifel Nicolaus Boosts Array BioPharma (ARRY) Price Target to $20.00
www.americanbankingnews.com - January 22 at 8:00 AM
Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 TrialCombination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial
www.prnewswire.com - January 20 at 12:10 PM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - January 18 at 3:22 PM
ARRY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018ARRY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - January 18 at 3:22 PM
Lunsen Gil J. Van Sells 21,500 Shares of Array BioPharma Inc. (ARRY) StockLunsen Gil J. Van Sells 21,500 Shares of Array BioPharma Inc. (ARRY) Stock
www.americanbankingnews.com - January 17 at 7:04 PM
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Array BioPharma Inc. (Nasdaq: ARRY) To Contact The FirmFINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Array BioPharma Inc. (Nasdaq: ARRY) To Contact The Firm
finance.yahoo.com - January 17 at 3:21 PM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRYEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY
finance.yahoo.com - January 17 at 3:21 PM
Array BioPharma Inc. (ARRY) CFO Sells $102,975.00 in StockArray BioPharma Inc. (ARRY) CFO Sells $102,975.00 in Stock
www.americanbankingnews.com - January 16 at 7:42 PM
Array BioPharma to Present Updated Phase 3 BEACON CRC Safety Lead-In Results of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the 2018 Gastrointestinal Cancers SymposiumArray BioPharma to Present Updated Phase 3 BEACON CRC Safety Lead-In Results of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the 2018 Gastrointestinal Cancers Symposium
finance.yahoo.com - January 16 at 3:20 PM
ARRY LOSS ALERT: Rosen Law Firm Reminds Array Biopharma Inc. Investors of Important January 22 Deadline in ... - GlobeNewswire (press release)ARRY LOSS ALERT: Rosen Law Firm Reminds Array Biopharma Inc. Investors of Important January 22 Deadline in ... - GlobeNewswire (press release)
globenewswire.com - January 13 at 7:12 AM
ARRY LOSS ALERT: Rosen Law Firm Reminds Array Biopharma Inc. Investors of Important January 22 Deadline in Class Action– ARRYARRY LOSS ALERT: Rosen Law Firm Reminds Array Biopharma Inc. Investors of Important January 22 Deadline in Class Action– ARRY
finance.yahoo.com - January 13 at 7:12 AM
The Klein Law Firm Reminds Shareholders of a Class Action Commenced on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY)The Klein Law Firm Reminds Shareholders of a Class Action Commenced on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY)
finance.yahoo.com - January 12 at 3:19 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRYSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY
finance.yahoo.com - January 12 at 3:19 PM
Traders Purchase High Volume of Array BioPharma Call Options (ARRY)Traders Purchase High Volume of Array BioPharma Call Options (ARRY)
www.americanbankingnews.com - January 12 at 1:28 AM
Array BioPharma Target of Unusually Large Options Trading (ARRY)Array BioPharma Target of Unusually Large Options Trading (ARRY)
www.americanbankingnews.com - January 12 at 1:28 AM
Stocks Showing Market Leadership: Array Biopharma Earns 91 RS RatingStocks Showing Market Leadership: Array Biopharma Earns 91 RS Rating
finance.yahoo.com - January 10 at 3:21 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRYSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY
finance.yahoo.com - January 9 at 3:20 PM
 Analysts Anticipate Array BioPharma Inc. (ARRY) Will Announce Quarterly Sales of $24.82 Million Analysts Anticipate Array BioPharma Inc. (ARRY) Will Announce Quarterly Sales of $24.82 Million
www.americanbankingnews.com - January 9 at 11:52 AM
ARRY INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018ARRY INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - January 8 at 3:24 PM
 Analysts Expect Array BioPharma Inc. (ARRY) Will Announce Earnings of -$0.23 Per Share Analysts Expect Array BioPharma Inc. (ARRY) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - January 7 at 7:18 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRYSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY
finance.yahoo.com - January 5 at 3:23 PM
Array BioPharma Inc. to Post FY2019 Earnings of ($0.51) Per Share, Cantor Fitzgerald Forecasts (ARRY)Array BioPharma Inc. to Post FY2019 Earnings of ($0.51) Per Share, Cantor Fitzgerald Forecasts (ARRY)
www.americanbankingnews.com - January 4 at 11:08 PM
Array BioPharma (ARRY) Cut to "Sell" at Zacks Investment ResearchArray BioPharma (ARRY) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 4 at 5:52 PM
Array BioPharma Inc. (ARRY) Receives Consensus Rating of "Buy" from AnalystsArray BioPharma Inc. (ARRY) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 2 at 8:02 AM
Array BioPharma Inc. (ARRY) Short Interest Down 23.4% in DecemberArray BioPharma Inc. (ARRY) Short Interest Down 23.4% in December
www.americanbankingnews.com - December 30 at 3:11 AM
ARRY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018ARRY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - December 29 at 3:20 PM
The Klein Law Firm Reminds Shareholders of a Class Action on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY)The Klein Law Firm Reminds Shareholders of a Class Action on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY)
finance.yahoo.com - December 27 at 3:07 PM
Array Biopharma Shows Rising Price Performance With Jump To 85 RS RatingArray Biopharma Shows Rising Price Performance With Jump To 85 RS Rating
finance.yahoo.com - December 26 at 1:19 PM
Array BioPharma Inc. (ARRY) Expected to Post Quarterly Sales of $24.82 MillionArray BioPharma Inc. (ARRY) Expected to Post Quarterly Sales of $24.82 Million
www.americanbankingnews.com - December 24 at 6:22 PM
Array BioPharma (ARRY) Price Target Increased to $13.00 by Analysts at Jefferies GroupArray BioPharma (ARRY) Price Target Increased to $13.00 by Analysts at Jefferies Group
www.americanbankingnews.com - December 23 at 7:46 PM
Array BioPharma Inc (NASDAQ:ARRY): Does -5.8% Earnings Drop In A Year Reflect The Long-Term Trend?Array BioPharma Inc (NASDAQ:ARRY): Does -5.8% Earnings Drop In A Year Reflect The Long-Term Trend?
finance.yahoo.com - December 23 at 3:37 PM
Array BioPharma (ARRY) Upgraded to "Hold" by BidaskClubArray BioPharma (ARRY) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - December 23 at 2:56 PM
Array Biopharma Trying To Close In On Key Technical BenchmarkArray Biopharma Trying To Close In On Key Technical Benchmark
finance.yahoo.com - December 22 at 3:36 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - December 22 at 3:36 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRYINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY
finance.yahoo.com - December 21 at 3:20 PM
Biotech Stocks Research Reports Released on Paratek Pharma ... - PR Newswire (press release)Biotech Stocks' Research Reports Released on Paratek Pharma ... - PR Newswire (press release)
www.prnewswire.com - December 21 at 7:01 AM
Array Biopharma Inc (ARRY) CEO Ron Squarer Sold $8.9 million of Shares - NasdaqArray Biopharma Inc (ARRY) CEO Ron Squarer Sold $8.9 million of Shares - Nasdaq
www.nasdaq.com - December 21 at 7:01 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline - ARRYSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline - ARRY
finance.yahoo.com - December 21 at 7:01 AM
First Week of February 2018 Options Trading For Array BioPharma (ARRY)First Week of February 2018 Options Trading For Array BioPharma (ARRY)
www.nasdaq.com - December 20 at 3:20 PM
Array Biopharma Inc (ARRY) CEO Ron Squarer Sold $8.9 million of SharesArray Biopharma Inc (ARRY) CEO Ron Squarer Sold $8.9 million of Shares
finance.yahoo.com - December 20 at 6:54 AM
Andrew R. Robbins Sells 282,874 Shares of Array BioPharma Inc. (ARRY) StockAndrew R. Robbins Sells 282,874 Shares of Array BioPharma Inc. (ARRY) Stock
www.americanbankingnews.com - December 19 at 11:32 PM
Insider Selling: Array BioPharma Inc. (ARRY) CEO Sells 819,671 Shares of StockInsider Selling: Array BioPharma Inc. (ARRY) CEO Sells 819,671 Shares of Stock
www.americanbankingnews.com - December 19 at 11:32 PM
ARRY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018ARRY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - December 19 at 7:10 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRYINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY
finance.yahoo.com - December 18 at 3:20 PM
ETFs with exposure to Array BioPharma, Inc. : December 18, 2017ETFs with exposure to Array BioPharma, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 3:20 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Array Biopharma Inc ... - GlobeNewswire (press release)SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Array Biopharma Inc ... - GlobeNewswire (press release)
globenewswire.com - December 17 at 6:54 AM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - December 15 at 3:21 PM

SEC Filings

Array BioPharma (NASDAQ:ARRY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Array BioPharma (NASDAQ:ARRY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Array BioPharma (NASDAQ ARRY) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.